29 September 2022: Clinical Research
Postoperative Dynamic of Leptin and Fibroblast Growth Factor 21 in 123 Patients Recovering from Cardiac Surgery
Da Liu 1BCE , Danyal Ghani 2BCE , Wilson Y. Szeto 3ABE , Krzysztof Laudanski 456ABCDEFG*DOI: 10.12659/MSM.937652
Med Sci Monit 2022; 28:e937652
Table 1 Demographics and clinical characteristics of the study sample.
| Age, mean±SD [years] | 64.22±12.27 |
| Sex – Male no. (% of total) | 93 (75.6%) |
| BMI mean±SD [kg/m] | 28.4±5.99 |
| Race (% Caucasian, % Black, % Asian, % Other) | 83.7%, 6.5%, 4.1%, 5.7% |
| Duration of anesthesia; mean±SD [min] | 394.17±117.9 |
| Duration of surgery; mean±SD [min] | 277.75±100.92 |
| Coronary artery bypass surgery; no.* | 64 |
| Mitral valvuloplasty & replacement; no.* | 16 |
| Aortic valvuloplasty & replacement; no.* | 36 |
| Others; no.* | 6 |
| Estimated blood loss [ml] | 197.13±260.4 |
| Total crystalloid during surgery [ml] | 1254.91±606.24 |
| Corticosteroid administration (% of all cases) | 15.4% |
| Ketorolac administration (% of all cases) | 7.4% |
| Acetaminophen administration (% of all cases) | 71.3% |
| ASA administration (% of all cases) | 66.4% |
| APACHE score at 1 h, mean±SD | 17.08±6 |
| APACHE score at 24 h, mean±SD | 9.95±5.17 |
| APACHE score at 48 h, mean±SD | 9.33±4.99 |
| CCI median (95% CI) | 4 (3.7–4.53) |
| Acute Coronary Syndrome | 15.4% |
| Chronic heart failure | 22% |
| Connective tissue disease (non-active) | 15.4% |
| Cerebrovascular disease | 9.8% |
| Type 2 diabetes | 28.5% |
| COPD | 6.5% |
| Mortality | 1.6% |
| CVA | 9.8% |
| PE | 5.7% |
| DVT | 8.9% |
| AKI | 22.1% |
| * Some patients had more than one procedure. | |